Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico
Authors
Keywords
-
Journal
Human Vaccines & Immunotherapeutics
Volume 10, Issue 10, Pages 2853-2863
Publisher
Informa UK Limited
Online
2014-11-01
DOI
10.4161/21645515.2014.972131
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Optimization and Validation of a Plaque Reduction Neutralization Test for the Detection of Neutralizing Antibodies to Four Serotypes of Dengue Virus Used in Support of Dengue Vaccine Development
- (2013) Tatyana M. Timiryasova et al. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
- Efficacy of tetravalent dengue vaccine in Thai schoolchildren – Authors' reply
- (2013) Arunee Sabchareon et al. LANCET
- The global distribution and burden of dengue
- (2013) Samir Bhatt et al. NATURE
- Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA
- (2013) Gustavo H. Dayan et al. VACCINE
- The History of Dengue Outbreaks in the Americas
- (2012) Olivia Brathwaite Dick et al. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
- Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial
- (2012) Arunee Sabchareon et al. LANCET
- Dengue
- (2012) Cameron P. Simmons et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunogenicity and safety of tetravalent dengue vaccine in 2–11 year-olds previously vaccinated against yellow fever: Randomized, controlled, phase II study in Piura, Peru
- (2012) Claudio F. Lanata et al. VACCINE
- Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2–45 years
- (2012) Yee Sin Leo et al. Human Vaccines & Immunotherapeutics
- Dengue Infection in Children in Ratchaburi, Thailand: A Cohort Study. I. Epidemiology of Symptomatic Acute Dengue Infection in Children, 2006–2009
- (2012) Arunee Sabchareon et al. PLoS Neglected Tropical Diseases
- Interference and Facilitation Between Dengue Serotypes in a Tetravalent Live Dengue Virus Vaccine Candidate
- (2011) K. B. Anderson et al. JOURNAL OF INFECTIOUS DISEASES
- Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: Randomized controlled phase I trial in the Philippines
- (2011) Rosario Z. Capeding et al. VACCINE
- Review of dengue virus and the development of a vaccine
- (2010) Sarah Murrell et al. BIOTECHNOLOGY ADVANCES
- A Novel Tetravalent Dengue Vaccine Is Well Tolerated and Immunogenic against All 4 Serotypes inFlavivirus‐Naive Adults
- (2010) Dennis Morrison et al. JOURNAL OF INFECTIOUS DISEASES
- Heterotypic Dengue Infection with Live Attenuated Monotypic Dengue Virus Vaccines: Implications for Vaccination of Populations in Areas Where Dengue Is Endemic
- (2010) Anna P. Durbin et al. JOURNAL OF INFECTIOUS DISEASES
- Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City
- (2010) Jorge Poo et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Complete but curtailed T-cell response to very low-affinity antigen
- (2009) Dietmar Zehn et al. NATURE
- Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy
- (2009) Monika Simmons et al. VIROLOGY
- Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects
- (2008) Bruno Guy et al. VACCINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now